PCSK9抑制剂在动脉粥样硬化(Atherosclerosis, AS)疾病中的预防和影响作用  

Prevention and Influence of PCSK9 Inhibitors in Atherosclerotic (AS) Diseases

作　　者：王秀玲 耿强[2] 吴倩倩 王正忠[2] 

机构地区：[1]青岛大学医学部,山东 青岛 [2]青岛市市立医院心内科,山东 青岛

出　　处：《临床医学进展》2021年第12期5735-5739,共5页Advances in Clinical Medicine

摘　　要：动脉粥样硬化(AS)是众多血管性疾病的前期病理基础,受累动脉病变多开始于内膜,逐渐使动脉壁变硬变厚,失去弹性直至缺血、纤维化。PCSK9抑制剂(proprotein convertase subtilisin-kexin type 9 inhibitors)可通过降低low-density lipoprotein cholesterol (LDL-C)而逆转及减小动脉斑块的大小和体积,减轻血管壁的炎症,调节血管内皮功能,增加纤维帽的厚度及稳定性等多方面作用从而对AS疾病起到积极的预防作用。本文将系统阐述PCSK9抑制剂对AS疾病的进展及治疗中发挥的作用。Atherosclerosis (AS) is the pre-pathological basis of many vascular diseases. The affected arteries usually start from the intima, and gradually make the arterial wall hard and thick, lose its elasticity, until ischemia and fibrosis. PCSK9 inhibitors (proprotein convertase subtilisin-kexin type 9 inhibitors) can reverse and reduce the size and volume of arterial plaques by lowering LDL-C, reducing inflammation of blood vessel walls, regulating vascular endothelial function, and increasing the thickness and stability of the fibrous cap. It plays a positive role in the prevention of AS disease. This article will systematically describe the role of PCSK9 inhibitors in the progression and treatment of AS disease.

关 键 词：动脉粥样硬化 PCSK9抑制剂 脂蛋白a 动脉壁炎症 内皮细胞功能 动脉斑块纤维帽的厚度和 稳定性 

分 类 号：R54[医药卫生—心血管疾病]